Epigenetic switch at Atp2a2 and Myh7 gene promoters in pressure overload-induced heart failure

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Angrisano, Tiziana ^a   Schiattarella, Gabriele Giacomo ^a   Keller, Simona ^a   Pironti, Gianluigi ^a,b   Florio, Ermanno ^a   Magliulo, Fabio ^a   Bottino, Roberta ^a   Pero, Raffaela ^a   Lembo, Francesca ^a   Avvedimento, Enrico Vittorio ^a   Esposito, Giovanni ^a   Trimarco, Bruno ^a   Chiariotti, Lorenzo ^a   Perrino, Cinzia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; HISTONE; HISTONE DEMETHYLASE; HISTONE LYSINE SPECIFIC DEMETHYLASE 2A; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MYOSIN HEAVY CHAIN BETA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, MOUSE; CHROMATIN; FBXL11 PROTEIN, MOUSE; LYSINE; MYH7 PROTEIN, MOUSE; MYOSIN HEAVY CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; ATP2A2 GENE; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE SWITCHING; HEART VENTRICLE OVERLOAD; HISTONE METHYLATION; MALE; MOUSE; MYH7 GENE; NONHUMAN; PROMOTER REGION; TRANSVERSE AORTIC CONSTRICTION; ANIMAL; C57BL MOUSE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; HEART FAILURE; METABOLISM; PRESSURE;

ANIMALS; CHROMATIN; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HEART FAILURE; HISTONES; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LYSINE; MALE; MICE, INBRED C57BL; MYOSIN HEAVY CHAINS; PRESSURE; PROMOTER REGIONS, GENETIC; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84907476145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106024     Document Type: Article

References (33)

1. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, et al. (2006) Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 116: 1547-1560.
2. Francis GS, Chu C (1995) Compensatory and maladaptive responses to cardiac dysfunction. Curr Opin Cardiol 10: 260-267.
3. Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22: 6A-13A. (Pubitemid 23285789)
4. Perrino C, Rockman HA, Chiariello M (2006) Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. Vascul Pharmacol 45: 77-85. (Pubitemid 44374411)
5. Backs J, Olson EN (2006) Control of cardiac growth by histone acetylation/deacetylation. Circ Res 98: 15-24. (Pubitemid 43977219)
6. Olson EN, Backs J, McKinsey TA (2006) Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 274: 3-12; discussion 13-19, 152-155, 272-156.
7. Herron TJ, McDonald KS (2002) Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 90: 1150-1152. (Pubitemid 34786898)
8. Lipskaia L, Chemaly ER, Hadri L, Lompre AM, Hajjar RJ (2010) Sarcoplasmic reticulum Ca(2 +) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther 10: 29-41.
9. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92. (Pubitemid 34049147)
10. Sadoshima J, Izumo S (1997) The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59: 551-571. (Pubitemid 27142455)
11. Komuro I, Yazaki Y (1993) Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 55: 55-75. (Pubitemid 23102123)
12. Papait R, Greco C, Kunderfranco P, Latronico MV, Condorelli G (2013) Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol 108: 361.
13. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463. (Pubitemid 38715140)
14. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, et al. (2011) SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477: 601-605.
15. Gusterson RJ, Jazrawi E, Adcock IM, Latchman DS (2003) The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 278: 6838-6847. (Pubitemid 36800674)
16. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488. (Pubitemid 35232291)
17. Papait R, Cattaneo P, Kunderfranco P, Greco C, Carullo P, et al. (2013) Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A 110: 20164-20169.
18. Movassagh M, Choy MK, Knowles DA, Cordeddu L, Haider S, et al. (2011) Distinct epigenomic features in end-stage failing human hearts. Circulation 124: 2411-2422.
19. Movassagh M, Vujic A, Foo R (2011) Genome-wide DNA methylation in human heart failure. Epigenomics 3: 103-109.
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Schwarzbauer K, Bodenhofer U, Hochreiter S (2012) Genome-wide chromatin remodeling identified at GC-rich long nucleosome-free regions. PLoS One 7: e47924.
22. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, et al. (1993) Natriuretic peptide system in human heart failure. Circulation 88: 1004-1009. (Pubitemid 23264016)
23. Dirkx E, da Costa Martins PA and De Windt LJ (2013) Regulation of fetal gene expression in heart failure. Biochim Biophys Acta 1832: 2414-2424.
24. Hang CT, Yang J, Han P, Cheng HL, Shang C, et al. (2010) Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466: 62-67.
25. Tingare A, Thienpont B, Roderick HL (2013) Epigenetics in the heart: the role of histone modifications in cardiac remodelling. Biochem Soc Trans 41: 789-796.
26. Kouzarides T (2007) Chromatin modifications and their function. Cell 128: 693-705.
27. Shilatifard A (2006) Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 75: 243-269.
28. Haas J, Frese KS, Park YJ, Keller A, Vogel B, et al. (2013) Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 5: 413-429.
29. Kaneda R, Takada S, Yamashita Y, Choi YL, Nonaka-Sarukawa M, et al. (2009) Genome-wide histone methylation profile for heart failure. Genes Cells 14: 69-77.
30. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, et al. (2008) DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 319: 202-206.
31. Chambliss AB, Wu PH, Chen WC, Sun SX, Wirtz D (2013) Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution. FASEB J 27: 2667-2676.
32. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874. (Pubitemid 43255707)
33. Blackledge NP, Zhou JC, Tolstorukov MY, Farcas AM, Park PJ, et al. (2010) CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell 38: 179-190.